State of biomedical innovation conference
As policy agendas for 2015 come into sharper focus, much of the national conversation is aimed at tackling challenges in biomedical innovation. The first two months of the year alone have seen landmark proposals from Congress and the Obama Administration, including the House’s 21st Century Cures initiative, a bipartisan Senate working group focused on medical progress, President Obama’s Precision Medicine Initiative and a number of additional priorities being advanced by federal agencies and other stakeholders.
On March 13, the Engelberg Center for Health Care Reform hosted the State of Biomedical Innovation Conference to provide an overview of emerging policy efforts and priorities related to improving the biomedical innovation process. Senior leaders from government, academia, industry, and patient advocacy shared their thoughts on the challenges facing medical product development and promising approaches to overcome them. The discussion also examined the data and analyses that provide the basis for new policies and track their ultimate success.
Executive Director - Friends of Cancer Research
Executive Vice President, Science and Regulatory Advocacy - Pharmaceutical Research and Manufacturers of America (PhRMA)
Deputy Director, National Center for Advancing Translational Sciences - National Institutes of Health
Executive Director - Clinical Trials Transformation Initiative
Senior Vice President - IMS Health
Partner - Deerfield Management
Professor of Medicine, Sackler School of Graduate Biomedical Sciences - Tufts University
Director of Economics Staff, Office of Strategic Programs, Center for Drug Evaluation and Research - U.S. Food and Drug Administration
To subscribe or manage your subscriptions to our top event topic lists, please visit our event topics page.